{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Agent Affecting Blood or Body Fluid" in comments (approximate match)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Tripamide is a new diuretic derived from a sulfonamide nucleus that has both antihypertensive and natriuretic properties. It is Na-K-Cl cotransporter inhibitor. The antihypertensive mechanism of tripamide is considered to be based on a mild saluretic action and a peripheral vasodilation action. Tripamide is an ingredient of Normonal in Japan, indicated for the treatment of essential hypertension.
Status:
Possibly Marketed Outside US
Source:
Fragivix by Schwarz Pharma AG
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Benzarone is a human uric acid transporter 1 inhibitor and causes hepatotoxicity.
Status:
Possibly Marketed Outside US
Source:
Hydrion
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AMBUSIDE is a benzenesulfonamide-based diuretic used as an antihypertensive drug.
Status:
Withdrawn
Source:
Exifone [France]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Exifone, a drug recently proposed for the treatment of cognitive deficiencies of old age, has been marketed in France beginning in April 1988. It demonstrated remarkable anti-radical properties, but was withdrawal, because of the hepatotoxicity.
Status:
US Approved Rx
(1981)
First approved in 1981
Class:
MIXTURE
Status:
US Approved Rx
(2005)
First approved in 1979
Class:
MIXTURE
Status:
US Approved Rx
(1978)
First approved in 1978
Class:
MIXTURE
Status:
US Previously Marketed
Source:
CALCIUM GLUCEPTATE by ABRAXIS PHARM
(1987)
Source URL:
First approved in 1961
Source:
CALCIUM GLUCEPTATE by LILLY
Source URL:
Class:
MIXTURE
Conditions:
Calcium gluceptate (also known as calcium glucoheptonate) was used, as calcium supplements by people who were unable to get enough calcium or who was needed it more. This drug was used to prevent and to treat several conditions, related to the hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones; it is also needed for the heart, muscles, and nervous system to work properly. Nevertheless, that use of calcium gluceptate was discontinued.
Status:
Possibly Marketed Outside US
Source:
Glycophos by Fresenius Kabi USA, LLC
(2013)
Source URL:
First approved in 2013
Source:
Glycophos by Fresenius Kabi USA, LLC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA065488
(1991)
Source URL:
First approved in 1989
Source:
21 CFR 343
Source URL:
Class:
MIXTURE
